CDR-Life Announces Fourth Milestone Achievement with Boehringer Ingelheim in Phase 1 Geographic Atrophy Trial
April 30 2024 - 5:00AM
CDR-Life Inc. today announced the advancement of the Phase 1 study
with BI 771716, its therapeutic candidate in partnership with
Boehringer Ingelheim (BI) for the treatment of geographic atrophy
(GA). This marks the achievement of the fourth milestone under the
collaboration and licensing agreement between BI and CDR-Life.
BI 771716 is an antibody fragment-based compound. Its reduced
size enables optimized retinal layer-penetration to the most
critical target site driving GA disease pathology.
“We are thrilled by the continued success of our long-term
partnership with Boehringer Ingelheim and the progression of BI
771716 in this Phase 1 trial as evident by the achievement of this
fourth milestone payment,” said Christian Leisner, Ph.D., Chief
Executive Officer at CDR-Life. “Together with Boehringer Ingelheim,
we are hopeful that this candidate has the potential to
significantly slow down the progression of GA, bringing a
much-needed treatment option to the millions of patients who are
living with this devasting disease.”
CDR-Life and BI announced the collaboration and licensing
agreement in May 2020, followed by the selection of an antibody
fragment-based therapeutic candidate in September 2021. The
companies have executed on all milestones to date.
About Geographic Atrophy (GA)
GA is a chronic and progressive, irreversible retinal disease
that occurs in people with late-stage dry age-related macular
degeneration (AMD) impacting the ability to see. More than 5
million people worldwide suffer from GA, of which more than 40% are
legally blind. GA worsens with age, affecting 1 in 29 people above
the age of 75 and 1 in 4 people above 90. Consequently, rising
incidences are expected in aging populations.
About CDR-Life
CDR-Life is developing powerful T-cell engagers (TCE) to
eradicate hard-to-treat solid tumors. Our integrated antibody-based
TCE platform unlocks access to a wide range of cancer antigens. We
are leveraging this platform to advance a pipeline of potent and
selective TCE therapeutics targeting intracellular and surface
tumor antigens. With a team of proven drug development experts and
backed by leading cross-Atlantic investors, we are working to
empower patients’ own immune systems to eliminate tumors.
Contacts
Media:
Lauren Arnold
MacDougall Advisors
LArnold@macdougall.bio